Brought to you by 
Otsuka pays up to $302mm for license to Click's CT152 for MDD
11 Jan 2019
Executive Summary
Otsuka Pharmaceutical Co. Ltd. will ally with Click Therapeutics Inc. to develop and commercialize the latter's mobile software application CT152 as a prescription digital therapeutic for major depressive disorder (MDD) to treat patients either independently or in conjunction with other prescribed pharmaceuticals.
Deal Industry
- Digital Health
- Medical Devices
- Pharmaceuticals
Deal Status
- Final
Deal Type
-
Alliance
- Includes Royalty or Profit Split Information
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Otsuka pays up to $302mm for license to Click's CT152 for MDD
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice